Navigation Links
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/26/2009

purpura, rheumatoid arthritis, interstitial nephritis, lupus-like syndrome, sarcoidosis, aggravated psoriasis, urticaria, injection site necrosis, vasculitis and phototoxicity.

Additional serious adverse events included hallucinations. bipolar disorder, mania, encephalopathy (usually elderly treated with higher doses of PEGINTRON), hypotension, tachycardia, retinopathy including macular edema, retinal hemorrhage, cotton wool spots, papilledema, ischemic and hemorrhagic cerebrovascular events, bone marrow toxicity (cytopenia and very rarely aplastic anemia), thyroiditis, dental and periodontal disorders, hemorrhagic/ischemic colitis, dyspnea, pulmonary infiltrates, pneumonia, interstitial pneumonitis, hepatic failure, increases in serum creatinine in patients with renal insufficiency, acute hypersensitivity (angioedema, bronchoconstriction, anaphylaxis and cutaneous eruptions) and hypertriglyceridemia.

During the course of therapy lasting up to 48 weeks in patients ages 3 through 17 years receiving PEGINTRON/REBETOL combination therapy, weight loss and growth inhibition were common.

Patients receiving PEGINTRON and REBETOL as retreatment after failing a previous interferon combination regimen reported adverse reactions similar to those previously associated with this regimen during clinical trials of treatment-naive patients.

Please see important full U.S. prescribing information and the Medication Guide for PEGINTRON at www.schering-plough.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, an
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- goBalto, Inc., the leading provider of cloud-based clinical study ... Red Herring,s Top 100 Global award. goBalto ... in 2013, marking its emergence as a top player ... Top 100 Global list has become a mark of ... Herring editors were among the first to recognize that ...
(Date:11/26/2014)... , Nov. 25, 2014  Medtronic,s roughly ... has been widely discussed in the media for ... creating a stronger leading player in one of ... Information.  The healthcare market research firm said  the ... feature a diverse set of solutions spanning inpatient ...
(Date:11/26/2014)... Heska Corporation (NASDAQ: HSKA ) - ( ... advanced veterinary diagnostic and other specialty veterinary products , announced ... The Benchmark Company, LLC,s Micro Cap Discovery Conference on Thursday, ... The Palmer House Hilton, 17 E. Monroe Street, ... Please email hska@haydenir.com or contact your Benchmark representative ...
Breaking Medicine Technology:goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Heska to Attend Benchmark Micro Cap Discovery Conference 2
... Drafted Perform at Similar Level as Those Without ReconstructionLAS ... at the 2009 American Orthopaedic Society of Sports Medicine ... collateral ligament (UCL) reconstruction prior to selection in the ... risk of future injury or affect the rate of ...
... experience does not always keep hands injury-freeLAS VEGAS, Feb. ... have been on the rise in recent years, with ... United States. Many of those injuries might be prevented ... today at the 2009 Annual Meeting of the ...
Cached Medicine Technology:Elbow Ligament Reconstruction Appears Not to Affect Future Professional Advancement in Baseball 2Experience Not Always the Best Prescription for Snowblowers 2Experience Not Always the Best Prescription for Snowblowers 3Experience Not Always the Best Prescription for Snowblowers 4
(Date:11/26/2014)... (PRWEB) November 26, 2014 The ... Cardiology have launched a partnership designed to improve ... for congestive heart failure (CHF) patients in the ... staff and Lourdes Cardiology team will help CHF ... supervised protocols. This partnership pairs the Cardiac Recovery ...
(Date:11/26/2014)... 2014 Increasing incidence rate of ... regulations are expected to be prime pharmacovigilance market ... of acute and chronic ailments has resulted in ... development. Moreover, growing adverse drug reaction related hospitalization ... become the need of the hour in the ...
(Date:11/26/2014)... NC (PRWEB) November 26, 2014 German ... of materials science can cause mesothelioma that looks and ... posted a new article on the research. Click ... the Fraunhofer Institute for Toxicology and Experimental Medicine in ... While all of the rats eventually developed ...
(Date:11/26/2014)... The city of San Diego, California, ... forward with a plan to recycle wastewater – also ... Kleyne supports the San Diego plan as part of ... to Kleyne, by recycling water that San Diego already ... be greatly reduced. (Spagat, E, “San Diego looks to ...
(Date:11/26/2014)... 2014 Loffler Companies has been selected ... Imaging, an online information and news publication for resellers ... sixth consecutive year Loffler has earned this prestigious award ... Elite Dealer Awards honor the best and the brightest ... Dealer honorees were chosen for their innovative marketing and ...
Breaking Medicine News(10 mins):Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 3Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2
... new modus operandi at Britain’s farm ministry, with a view ... in the bud, as a preparation before the autumn season. ... gulls and waders, seen as potential H5N1 disseminators of infection ... surveillance and testing in the areas frequented by migratory birds. ...
... adults are estimated to use complementary and alternative therapies ... results of a// national survey published in the September ... issue on sleep. ,Approximately 10 to 34 ... as insomnia, according to background information in the article. ...
... Thiruvananthapuram said that there was no need to panic after ... were reported in the city.// ,Health authorities said that ... to pelt the state. The chikungunya scare so far was ... be confined to some pockets as mosquitoes are increasing due ...
... mosquito-caused illness is causing panic in the city.// ,As per ... city but four patients with its symptoms are being treated. Their ... have already started a survey in the city to identify chikungunya ... medical officer D.C. Jain. ,However, there is panic in ...
... fires have forced over 1,300 people to leave their ... to battle// the hundreds of forest fires on Friday. ... worst that they have ever encountered at this time ... with smoke vulnerability like children, the elderly, the infirm ...
... study directed by Mount Sinai School of Medicine ... regimens// might halt or even reverse symptoms of ... Attenuates Alzheimer’s Disease Type Brain Amyloidosis in Squirrel ... will be published in the November 2006 issue ...
Cached Medicine News:Health News:About 5 Percent of Adults with Insomnia Use Alternative Therapies 2Health News:Chikungunya Outbreak Feared in Jaipur 2Health News:Burning fires in Northern Ontario Cause Hundreds to leave their Homes 2Health News:Calorie Restriction May Prevent, Reduce Alzheimer’s Neuropatholog 2
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... is a rapid ELISA test for Clostridium ... value and 99% sensitivity. That means the ... out C. difficile negatives - which can ... before culturing for the organism - and ...
... is a rapid immunoassay to detect Clostridium difficile ... test uses antibodies specific for toxins A and ... and >99% specificity compared to tissue culture. Because ... B, the risk of false negative results due ...
Medicine Products: